Levstek, T.; Karun, T.; Rehberger Likozar, A.; Šebeštjen, M.; Trebušak Podkrajšek, K.
Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors. Genes 2023, 14, 632.
https://doi.org/10.3390/genes14030632
AMA Style
Levstek T, Karun T, Rehberger Likozar A, Šebeštjen M, Trebušak Podkrajšek K.
Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors. Genes. 2023; 14(3):632.
https://doi.org/10.3390/genes14030632
Chicago/Turabian Style
Levstek, Tina, Tina Karun, Andreja Rehberger Likozar, Miran Šebeštjen, and Katarina Trebušak Podkrajšek.
2023. "Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors" Genes 14, no. 3: 632.
https://doi.org/10.3390/genes14030632
APA Style
Levstek, T., Karun, T., Rehberger Likozar, A., Šebeštjen, M., & Trebušak Podkrajšek, K.
(2023). Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors. Genes, 14(3), 632.
https://doi.org/10.3390/genes14030632
